drug

Functional magnetic resonance imaging

functional magnetic resonance imaging
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
PROCEDURE
Pre-approval / investigational in the US
Developed by National Institute of Mental Health (NIMH)
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
PROCEDURE

Indications

Trials

2
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
NCT00548327Phase 2Terminated
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
NCT00288340—Completed

KOLs & investigators

2
Adam Anderson, Ph.D.
Jose A Apud, M.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
National Institute of Mental Health (NIMH)
company
trial
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
PHASE2
trial
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
NA
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Hallucinations
indication
Cognition Disorders
indication
KOL
Adam Anderson, Ph.D.
KOL score —
person
Jose A Apud, M.D.
KOL score —
person